{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:41:25Z","timestamp":1791499285917,"version":"4.3.4"},"reference-count":88,"publisher":"Informa UK Limited","issue":"29","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019450","name":"Verastem Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019450","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,12,8]]},"DOI":"10.1080\/14796694.2025.2582805","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T03:25:07Z","timestamp":1762399507000},"page":"3833-3843","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Unmet needs and emerging therapeutics in low-grade serous ovarian carcinoma: from chemoresistance to precision medicine"],"prefix":"10.1080","volume":"21","author":[{"given":"Brian M.","family":"Slomovitz","sequence":"first","affiliation":[{"name":"Mount Sinai Medical Center","place":["Miami Beach, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Podder","sequence":"additional","affiliation":[{"name":"Mount Sinai Medical Center","place":["Miami Beach, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Crane","sequence":"additional","affiliation":[{"name":"Wake Forest University","place":["Charlotte, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jubilee","family":"Brown","sequence":"additional","affiliation":[{"name":"Levine Cancer Institute at Atrium Health, Wake Forest University","place":["Charlotte, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"e_1_3_5_2_1","volume-title":"Cancer Tomorrow [Internet]","author":"Estimated number of new cases from 2022 to 2050, incidence, both sexes, age [0\u201385+]: Ovary","year":"2025","unstructured":"Estimated number of new cases from 2022 to 2050, incidence, both sexes, age [0\u201385+]: Ovary. Cancer Tomorrow [Internet]. Lyon, France: International Agency for Research on Cancer; 2025 [cited 2025 Sep 20]. Available from: https:\/\/gco.iarc.fr\/tomorrow\/en\/dataviz\/tables?cancers=25&single_unit=10000&years=2050"},{"key":"e_1_3_5_3_1","unstructured":"Ovarian cancer statistics [Internet]. New York (NY): Ovarian Cancer Research Alliance. 2025 [cited 2025 Jul 28]. Available from: https:\/\/ocrahope.org\/for-patients\/gynecologic-cancers\/ovarian-cancer\/ovarian-cancer-statistics"},{"key":"e_1_3_5_4_1","unstructured":"Cancer stat facts: ovarian cancer [Internet]. Bethesda (MD): National Cancer Institute. 2025 [cited 2025 Jul 28]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00952-5"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1399979"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102497"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63708-X"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16193268"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-34627-5"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12020458"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.14518"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkae049"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.970918"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.11.005"},{"key":"e_1_3_5_16_1","volume-title":"NCCN clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Version 3","author":"NCCN Guidelines Panel","year":"2025","unstructured":"NCCN Guidelines Panel. NCCN clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Version 3. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2025 Jul 16 [cited 2025 Jul 21]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13123035"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.5545"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01164"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02175-9"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00112"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000926"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01348"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.5522"},{"key":"e_1_3_5_25_1","volume-title":"Avmapkitm fakzynjatm co-pack [Prescribing information]","year":"2025","unstructured":"Avmapkitm fakzynjatm co-pack [Prescribing information]. Needham (MA): Verastem, Inc; 2025 [cited 2025 May 30]. Available from: https:\/\/www.verastem.com\/pdf\/avmapki-fakzynja-co-pack-full-prescribing-information.pdf"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8659754"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.12.033"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20210478"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051336"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000034306"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a011254"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4183"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317733984"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01705-z"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.364"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep26191"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10166"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01315-y"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp0901926"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000001867"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50786-z"},{"key":"e_1_3_5_42_1","volume-title":"First-of-its-kind, multi-national patient impact survey reveals unique challenges and gaps in care for patients with low-grade serous ovarian cancer [Internet]","year":"2023","unstructured":"First-of-its-kind, multi-national patient impact survey reveals unique challenges and gaps in care for patients with low-grade serous ovarian cancer [Internet]. Needham (MA): Verastem Oncology; 2023 Nov 7 [cited 2025 Apr 16]. Available from: https:\/\/www.businesswire.com\/news\/home\/20231107926726\/en\/First-Of-Its-Kind-Multi-National-Patient-Impact-Survey-Reveals-Unique-Challenges-and-Gaps-in-Care-for-Patients-with-Low-Grade-Serous-Ovarian-Cancer"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004610"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt463"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1127683"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.01.005"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2014.397"},{"issue":"3","key":"e_1_3_5_48_1","first-page":"A72.3","article-title":"PR057\/# 745. Circulating tumour DNA surveillance in low grade serous ovarian carcinoma","volume":"34","author":"Hasson SP","year":"2024","unstructured":"Hasson SP, Proszek P, Patel N, et al. PR057\/# 745. Circulating tumour DNA surveillance in low grade serous ovarian carcinoma. Int J Gynecol Cancer. 2024;34(suppl 3):A72.3\u2013A73.","journal-title":"Int J Gynecol Cancer"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105198"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.03.001"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004745"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004854"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.01.022"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1503\/cjs.017020"},{"key":"e_1_3_5_55_1","unstructured":"Carboplatin [Package Insert]. Lake Forest (IL): Hospira; 2024. Available from: https:\/\/labeling.pfizer.com\/showlabeling.aspx?id=4379"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103799"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.03.011"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000190"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.01.027"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.02.037"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.08.004"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.0632"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.126337.1"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.01.038"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3937"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00340-6"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-005919"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0308"},{"issue":"5","key":"e_1_3_5_70_1","first-page":"205","article-title":"Redefining the standard of care for low-grade serous ovarian cancer","volume":"22","author":"Manning-Geist BL","year":"2024","unstructured":"Manning-Geist BL, Cantor T, O\u2019Cearhbhaill RE, et al. Redefining the standard of care for low-grade serous ovarian cancer. Clin Adv Hematol Oncol. 2024;22(5):205\u2013226.","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_3_5_71_1","volume-title":"FDA grants priority review to avutometinib\/defactinib combo in KRAS+ ovarian cancer [Internet]","author":"Sava J","year":"2025","unstructured":"Sava J. FDA grants priority review to avutometinib\/defactinib combo in KRAS+ ovarian cancer [Internet]. Cranbury (MA): Targeted Oncology; 2025 Jan 2 [cited 2025 Apr 16] Available from: https:\/\/www.targetedonc.com\/view\/fda-grants-priority-review-to-avutometinib-defactinib-combo-in-kras-ovarian-cancer"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03763-y"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70572-7"},{"key":"e_1_3_5_74_1","volume-title":"ClinicalTrials.Gov identifier NCT05601700","author":"Letrozole for estrogen\/progesterone receptor positive low-grade serous epithelial ovarian cancer: a randomized phase III trial (LEPRE Trial)","unstructured":"Letrozole for estrogen\/progesterone receptor positive low-grade serous epithelial ovarian cancer: a randomized phase III trial (LEPRE Trial). ClinicalTrials.Gov identifier NCT05601700. Bethesda (MD): National Library of Medicine; [cited 2025 Jul 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05601700"},{"key":"e_1_3_5_75_1","volume-title":"Identifier NRG GY-019 (ClinicalTrials.Gov identifier NCT04095364)","author":"A randomized phase III, two-arm trial of paclitaxel\/carboplatin\/Maintenance metrozole versus letrozole monotherapy in patients with stage II-IV, primary low-grade serous carcinoma of the ovary or peritoneum","unstructured":"A randomized phase III, two-arm trial of paclitaxel\/carboplatin\/Maintenance metrozole versus letrozole monotherapy in patients with stage II-IV, primary low-grade serous carcinoma of the ovary or peritoneum. Identifier NRG GY-019 (ClinicalTrials.Gov identifier NCT04095364). Philadelphia (PA): NRG Oncology; [cited 2025 Jul 28]. Available from: https:\/\/www.nrgoncology.org\/Clinical-Trials\/Protocol\/nrg-gy019?filter=nrg-gy019"},{"key":"e_1_3_5_76_1","volume-title":"ClinicalTrials.Gov identifier NCT04111978","author":"Maintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)","unstructured":"Maintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO). ClinicalTrials.Gov identifier NCT04111978. Bethesda (MD): National Library of Medicine; [cited 2025 Jul 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04111978"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2019.1631799"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00135"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.04.010"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-005229"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01897-1"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970220)74:1<57::AID-IJC10>3.0.CO;2-F"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2022.37"},{"issue":"10","key":"e_1_3_5_84_1","first-page":"2235","article-title":"Differences in mek inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines","volume":"6","author":"Fern\u00e1ndez ML","year":"2016","unstructured":"Fern\u00e1ndez ML, DiMattia GE, Dawson A, et al. Differences in mek inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines. Am J Cancer Res. 2016;6(10):2235\u20132251.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-0725-1"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-024-03869-x"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3962"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2024.101379"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16213590"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2582805","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:23:44Z","timestamp":1781000624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2582805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":88,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2025,12,8]]}},"alternative-id":["10.1080\/14796694.2025.2582805"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2582805","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-08-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}